Intraday Info: Abeona Therapeutics Inc (NASDAQ:ABEO) locked on 02/02/2017 at $4.90. It has average volume 252,836 whilst it totals volume 274,253. The company has EPS -0.52 and according to analysts next quarter EPS and next year estimate EPS will -0.14 and -0.59 respectively.
Ownership Summary: Abeona Therapeutics has total institutional ownership 17.43% while its total outstanding shares 40 millions that’s value of holdings $32 million.
Active Positions: In the latest year, ABEO 21 holders have raised its positions while it contains total 1,386,378 shares. And the strength of reduced positions holders and held positions holders are 19 and 1,119,706 respectively.
New and Sold Out Positions: In ABEO force of new positions holders 11 and it has total shares 671,962. And force of sold out positions holders 11 and it has 647,721 shares.
Comparison with Other Company: The Market Value of ABEO is $195,804 above from AbbVie Inc. market value which is $98M. Current Last Sale of ABEO is $4.9 below from AbbVie Inc. current last sale which is $60.89.
Abeona Therapeutics Inc. declared that the first excessive-dose challenge become enrolled in the ongoing phase 1/2 trial for ABO-102 (AAV-SGSH). the first-in-guy clinical trial makes use of a unmarried intravenous injection of AAV gene remedy for sufferers with MPS IIIA (Sanfilippo syndrome type A), a devastating lysosomal garage sickness that impacts every mobile and organ ensuing in neurocognitive decline, speech loss, lack of mobility, and untimely dying.
The continued phase 1/2 scientific trial, which has obtained FastTrack designation with the aid of the FDA, is designed to assess protection and initial indicators of efficacy of ABO-102 in patients suffering from MPS IIIA. Consistent with the layout of the trial, topics in the low-dose and high-dose cohorts received an unmarried, intravenous injection of ABO-102 to deliver the AAV viral vector systematically during the body to introduce a corrective copy of the gene that underlies the reason of the MPS IIIA disease, especially the CNS. Subjects are evaluated at a couple of time factors over the preliminary 6-months submit-injection for protection tests and preliminary signals of biopotency.